Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)

KRAKOW, Poland, Oct. 20, 2023 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies addressing emerging targets in oncology, announced today that it entered into a Clinical Trial Financial Support…